• Edgewise Therapeutics posted a wider net loss of $49 million, or $0.46 per share, in first quarter 2026, versus a net loss of $40.8 million, or $0.43 per share, a year earlier.
• R&D expense rose 16.03% to $42.7 million, due to higher clinical development activity for EDG-7500 and EDG-15400, partly offset by lower sevasemten program costs tied to timing in GRAND CANYON and patient rollover into MESA.
• G&A expense climbed 25% to $11.5 million, on higher personnel-related costs and increased professional fees.
• Cash, cash equivalents and marketable securities totaled $499.6 million as of March 31, 2026.
• Positive long-term MESA data showed functional stabilization on sevasemten in Becker muscular dystrophy up to 3.5 years; CIRRUS-HCM 12-week Part D data for EDG-7500 expected in Q2 2026, with GRAND CANYON top-line results expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605070800PR_NEWS_USPR_____LA52852) on May 07, 2026, and is solely responsible for the information contained therein.